TriangleILKN421H (NCT07452224)
ILKN421H trial for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT07452224). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced non-small-cell lung cancer without specified driver alterations, including EGFR, ALK, and ROS1. Cohorts enroll patients after checkpoint-treatment failure regardless of PD-L1, or untreated patients with PD-L1 tumor-proportion score at least one percent.
The idea: pembrolizumab releases the PD1 immune brake. Researchers add investigational ILKN421H at either 1.6 or 2.4 milligrams to test response and safety. Both are infused every three weeks; ILKN421H starts at least four hours after pembrolizumab ends.
This phase 2 study plans 80 patients. iLeukon Therapeutics sponsors; two US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.